Kisunla (donanemab) is approved to be given as an injection via infusion about every four weeks in patients experiencing mild cognitive impairment or mild dementia, according to the FDA.
In phase 3 clinical trials, Kisunla slowed cognitive and functional decline by up to 35% compared to a placebo, according to a news release from Eli Lilly. The drug was also found to reduce participants’ risk of progressing further to the next stage of Alzheimer’s.
The treatment is not meant to be ongoing and can be stopped when the plaques dissipate to a certain level.
“As a physician, I am encouraged by the potential to stop treatment, which could reduce out-of-pocket costs and infusion burden for eligible patients,” Howard Fillit, MD, cofounder and chief science officer at the Alzheimer’s Drug Discovery Foundation said in the release.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.